Truist raised the firm’s price target on Guardian Pharmacy (GRDN) to $34 from $30 and keeps a Buy rating on the shares. The firm has updated its model to reflect the company’s Q3 earnings beat and guidance raise, the analyst tells investors in a research note. Truist is positive on Guardian’s leading positioning in the fragmented long-term care pharmacy industry which carries “brisk overarching secular demand drivers”.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN: